Recently, the A-share market style has changed. The strong technology sector in the early stages has ushered in adjustments. The pharmaceutical sector, which has been dormant for a long time, has begun a strong rebound, and the net worth of many active pharmaceutical funds has risen sharply, becoming the main focus of the market. According to Wind statistics, as of August 14, a number of active equity pharmaceutical funds had increased by more than 30% in the range, and the earnings performance of leading products was particularly outstanding. Among them, China Merchants Frontier Healthcare, China Merchants Healthcare, and Huatai Berry Healthcare increased by more than 54%, 53%, and 52% respectively, leading similar pharmaceutical funds; products such as Harvest Healthcare and GF Pharmaceuticals increased by more than 40%; more than 10 pharmaceutical-themed funds, including Jianxin High-End Healthcare, China-Europe Healthcare Innovation, Cathay Pacific Innovative Pharmaceuticals, and China-Europe Healthcare, all surpassed 30%. The overall profit effect was remarkable. Industry agency analysis indicates that the current pharmaceutical market is dominated by industry trends and structural opportunities, and has not yet entered the stage of capital gathering and market congestion. The net value of funds rebounded first, but ETF funds and overall institutional holdings have yet to follow up and fill positions, and the low level characteristics of the industry are obvious. If the fundamentals of the industry continue to be implemented and corporate performance continues to be realized, the current low institutional allocation ratio will leave sufficient room for subsequent incremental capital to return and for the sector to continue to rise.

Recently, the A-share market style has changed. The strong technology sector in the early stages has ushered in adjustments. The pharmaceutical sector, which has been dormant for a long time, has begun a strong rebound, and the net worth of many active pharmaceutical funds has risen sharply, becoming the main focus of the market. According to Wind statistics, as of August 14, a number of active equity pharmaceutical funds had increased by more than 30% in the range, and the earnings performance of leading products was particularly outstanding. Among them, China Merchants Frontier Healthcare, China Merchants Healthcare, and Huatai Berry Healthcare increased by more than 54%, 53%, and 52% respectively, leading similar pharmaceutical funds; products such as Harvest Healthcare and GF Pharmaceuticals increased by more than 40%; more than 10 pharmaceutical-themed funds, including Jianxin High-End Healthcare, China-Europe Healthcare Innovation, Cathay Pacific Innovative Pharmaceuticals, and China-Europe Healthcare, all surpassed 30%. The overall profit effect was remarkable. Industry agency analysis indicates that the current pharmaceutical market is dominated by industry trends and structural opportunities, and has not yet entered the stage of capital gathering and market congestion. The net value of funds rebounded first, but ETF funds and overall institutional holdings have yet to follow up and fill positions, and the low level characteristics of the industry are obvious. If the fundamentals of the industry continue to be implemented and corporate performance continues to be realized, the current low institutional allocation ratio will leave sufficient room for subsequent incremental capital to return and for the sector to continue to rise.